Subject(s)
European Union/organization & administration , Gastroenterology/statistics & numerical data , Societies, Medical/organization & administration , 2019-nCoV Vaccine mRNA-1273/pharmacology , Administration, Intravenous , Antibiotic Prophylaxis/methods , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/therapeutic use , Cholecystectomy/methods , Cholecystectomy/standards , Clinical Trials as Topic , Colitis, Ulcerative/drug therapy , Crohn Disease , Emergency Treatment , Endoscopy/methods , Gastroenterology/organization & administration , Gastroparesis/surgery , Heterocyclic Compounds, 3-Ring/therapeutic use , Humans , Inflammatory Bowel Diseases/drug therapy , Inflammatory Bowel Diseases/immunology , Janus Kinase Inhibitors/therapeutic use , Myotomy/methods , Preoperative Care , Remission Induction , Treatment Outcome , Tumor Necrosis Factor Inhibitors/adverse effects , Tumor Necrosis Factor Inhibitors/therapeutic use , User-Computer InterfaceABSTRACT
Following the spread of the infection from the new SARS-CoV2 coronavirus in March 2020, several surgical societies have released their recommendations to manage the implications of the COVID-19 pandemic for the daily clinical practice. The recommendations on emergency surgery have fueled a debate among surgeons on an international level.We maintain that laparoscopic cholecystectomy remains the treatment of choice for acute cholecystitis, even in the COVID-19 era. Moreover, since laparoscopic cholecystectomy is not more likely to spread the COVID-19 infection than open cholecystectomy, it must be organized in such a way as to be carried out safely even in the present situation, to guarantee the patient with the best outcomes that minimally invasive surgery has shown to have.